TXNRD2

Thioredoxin reductase 2, mitochondrial · Q9NNW7 · TXNRD2 on Sugi Atlas →

9,194 patent compounds predicted against TXNRD2, 6,340 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gamma-Cyclodextrin (SCHEMBL8768)	0.77	6/20
Betadex (SCHEMBL24215)	0.77	6/20
Alfadex (SCHEMBL24981)	0.77	6/20
Betadex (SCHEMBL127367)	0.77	6/20
Gamma-Cyclodextrin (SCHEMBL180792)	0.77	6/20
Alfadex (SCHEMBL181370)	0.77	6/20
Betadex (SCHEMBL434559)	0.77	6/20
SCHEMBL466130	0.77	6/20
Betadex (SCHEMBL692932)	0.74	6/20
Betadex (SCHEMBL1395831)	0.74	6/20
Betadex (SCHEMBL441667)	0.61	6/20
SCHEMBL890314	0.59	6/20
SCHEMBL1193222	0.59	6/20
SCHEMBL398655	0.53	6/20
SCHEMBL432885	0.53	6/20
SCHEMBL1056613	0.53	6/20
SCHEMBL1614698	0.51	6/20
Betadex (SCHEMBL193191)	0.50	6/20
Betadex (SCHEMBL306328)	0.49	6/20
SCHEMBL8265	0.43	6/20

Clinical trials — most relevant to TXNRD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients	PHASE4	UNKNOWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression	PHASE2/PHASE3	NOT_YET_RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation	PHASE2	COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy	PHASE2	RECRUITING
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
Macrophage Migration Inhibitory Factor (MIF)- Cardiac Surgery	nan	COMPLETED
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)	nan	RECRUITING
Angiogenesis Induced in the Elderly by Hyperbaric Oxygen Therapy	nan	COMPLETED
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults	nan	COMPLETED
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients	nan	UNKNOWN
Relation of White Blood Cell Function to Diabetes	nan	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder	nan	COMPLETED
Effects of Preoperative Oral Carbohydrate Loading on Maternal Thiol-disulfide Homeostasis	nan	COMPLETED
Thiol/Disulphide Homeostasis in Unexplained Infertility	nan	COMPLETED
Mitochondrial Dysfunction in Diabetes	nan	COMPLETED
Human Adaptation to High Altitude	nan	UNKNOWN
Mitochondria Oxidative Stress and Vascular Health Study	nan	COMPLETED
Diabetic Cardiomyopathy and Heart Failure	nan	WITHDRAWN
Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TXNRD2 binder may also engage these)

Protein	Name	Similarity
Q9JLT4	—	1.000	Q9JLT4 →
Q9N2I8	—	0.998	Q9N2I8 →
Q9Z0J5	—	0.997	Q9Z0J5 →
Q9VNT5	—	0.994	Q9VNT5 →
TXNRD1	Thioredoxin reductase 1, cytoplasmic	0.993	landscape →
GSR	Glutathione reductase, mitochondrial	0.992	landscape →
O62768	—	0.991	O62768 →
P91938	—	0.989	P91938 →
P47791	—	0.989	P47791 →
A2TIL1	—	0.989	A2TIL1 →
P39050	—	0.988	P39050 →
P70619	—	0.988	P70619 →
O89049	—	0.987	O89049 →
TXNRD3	Thioredoxin reductase 3	0.987	landscape →
Q5NVA2	—	0.986	Q5NVA2 →
Q99MD6	—	0.985	Q99MD6 →
B9A1H3	—	0.985	B9A1H3 →
Q9MYY8	—	0.985	Q9MYY8 →
Q43154	—	0.984	Q43154 →
P78965	—	0.984	P78965 →
P28593	—	0.984	P28593 →
P39051	—	0.984	P39051 →
P48642	—	0.984	P48642 →
P13110	—	0.983	P13110 →
P27456	—	0.983	P27456 →
Q8S3R2	—	0.981	Q8S3R2 →
Q9LK94	—	0.981	Q9LK94 →
P30635	—	0.980	P30635 →
P22570	—	0.980	P22570 →
Q6C5H4	—	0.979	Q6C5H4 →